Journal Article

DKFZ-2023-00516

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.

Mircetic, J.DKFZ* ; Camgöz, A.DKFZ* ; Abohawya, M.DKFZ* ; Ding, L. ; Dietzel, J. ; Tobar, S. G. ; Paszkowski-Rogacz, M. ; Seidlitz, T. ; Schmäche, T. ; Mehnert, M.-C. ; Sidorova, O. ; Weitz, J. ; Buchholz, F. ; Stange, D. E.DKFZ*

2023
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/smtd.202201605

Abstract: Viability CRISPR screens have proven indispensable in parsing genome function. However, their application in new, more physiologically relevant culturing systems like patient-derived organoids (PDOs) has been much slower. To probe epigenetic contribution to gastric cancer (GC), the third leading cause of cancer-related deaths worldwide, the first negative selection CRISPR screen in GC PDOs that faithfully preserve primary tumor characteristics is performed. Extensive quality control measurements showing feasibility of CRISPR screens in primary organoid culture are provided. The screen reveals the histone lysine demethylase-1A (KDM1A) to constitute a GC vulnerability. Both genetic and pharmacological inhibition of KDM1A cause organoid growth retardation. Further, it is shown that most of KDM1A cancer-supporting functions center on repression of N-myc downstream regulates gene-1 (NDRG1). De-repression of NDRG1 by KDM1A inhibitors (KDM1Ai) causes inhibition of Wnt signaling and a strong G1 cell cycle arrest. Finally, by profiling 20 GC PDOs, it is shown that NDRG1 upregulation predicts KDM1Ai response with 100% sensitivity and 82% specificity in the tested cohort. Thus, this work pioneers the use of negative selection CRISPR screens in patient-derived organoids, identifies a marker of KDM1Ai response, and accordingly a cohort of patients who may benefit from such therapy.

Keyword(s): CRISPR screen ; KDM1A-NDRG1 axis ; epigenetic regulators ; gastric cancer ; patient-derived organoids

Note: 2023 Jun;7(6):e2201605

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Dresden (DD01)
2. B062 Pädiatrische Neuroonkologie (B062)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2023

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---